BlackRock
FOLD

BlackRock’s Amicus Therapeutics FOLD Stock Holding History

BlackRock’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$490M Buy
33,879,048
+1,354,667
+4% +$19.4M 0.01% 1118
2025
Q4 		$463M Buy
32,524,381
+6,675,416
+26% +$65.6M 0.01% 1161
2025
Q3 		$204M Sell
25,848,965
-1,683,244
-6% -$12M ﹤0.01% 1654
2025
Q2 		$158M Sell
27,532,209
-291,563
-1% -$1.88M ﹤0.01% 1761
2025
Q1 		$227M Sell
27,823,772
-83,773
-0.3% -$775K ﹤0.01% 1520
2024
Q4 		$263M Buy
27,907,545
+1,800,546
+7% +$18.7M 0.01% 1505
2024
Q3 		$279M Buy
26,106,999
+1,735,340
+7% +$18.9M 0.01% 1464
2024
Q2 		$242M Buy
24,371,659
+1,522,210
+7% +$15.6M 0.01% 1498
2024
Q1 		$269M Sell
22,849,449
-138,690
-0.6% -$1.77M 0.01% 1446
2023
Q4 		$326M Buy
22,988,139
+2,046,362
+10% +$23.2M 0.01% 1320
2023
Q3 		$255M Buy
20,941,777
+43,184
+0.2% +$557K 0.01% 1381
2023
Q2 		$262M Buy
20,898,593
+1,160,568
+6% +$13.8M 0.01% 1392
2023
Q1 		$219M Sell
19,738,025
-400,053
-2% -$4.93M 0.01% 1477
2022
Q4 		$246M Buy
20,138,078
+239,526
+1% +$2.7M 0.01% 1375
2022
Q3 		$208M Sell
19,898,552
-351,306
-2% -$3.91M 0.01% 1443
2022
Q2 		$217M Buy
20,249,858
+656,857
+3% +$5.41M 0.01% 1465
2022
Q1 		$186M Sell
19,593,001
-217,347
-1% -$2.04M 0.01% 1728
2021
Q4 		$229M Buy
19,810,348
+224,150
+1% +$2.5M 0.01% 1631
2021
Q3 		$187M Sell
19,586,198
-716,072
-4% -$7.32M 0.01% 1763
2021
Q2 		$196M Sell
20,302,270
-1,219,609
-6% -$11.9M 0.01% 1776
2021
Q1 		$213M Sell
21,521,879
-355,563
-2% -$5.5M 0.01% 1686
2020
Q4 		$505M Buy
21,877,442
+908,634
+4% +$18.6M 0.02% 888
2020
Q3 		$296M Sell
20,968,808
-1,287,010
-6% -$18.8M 0.01% 1081
2020
Q2 		$336M Buy
22,255,818
+1,016,802
+5% +$12.4M 0.01% 975
2020
Q1 		$196M Buy
21,239,016
+382,909
+2% +$3.64M 0.01% 1186
2019
Q4 		$203M Buy
20,856,107
+127,862
+0.6% +$1.17M 0.01% 1478
2019
Q3 		$166M Buy
20,728,245
+2,147,832
+12% +$23.3M 0.01% 1540
2019
Q2 		$232M Buy
18,580,413
+1,805,661
+11% +$22.9M 0.01% 1321
2019
Q1 		$228M Buy
16,774,752
+252,932
+2% +$3.09M 0.01% 1319
2018
Q4 		$158M Buy
16,521,820
+147,484
+0.9% +$1.62M 0.01% 1490
2018
Q3 		$198M Buy
16,374,336
+357,035
+2% +$4.99M 0.01% 1509
2018
Q2 		$250M Buy
16,017,301
+927,049
+6% +$14M 0.01% 1288
2018
Q1 		$227M Buy
15,090,252
+1,378,155
+10% +$21M 0.01% 1258
2017
Q4 		$197M Buy
13,712,097
+342,861
+3% +$4.71M 0.01% 1395
2017
Q3 		$202M Buy
13,369,236
+1,587,278
+13% +$21M 0.01% 1340
2017
Q2 		$119M Sell
11,781,958
-185,638
-2% -$1.49M 0.01% 1690
2017
Q1 		$85.3M Buy
11,967,596
+11,955,760
+101,012% +$75.6M ﹤0.01% 1881
2016
Q4 		$59K Sell
11,836
-14,812
-56% -$103K ﹤0.01% 2849
2016
Q3 		$197K Buy
26,648
+205
+0.8% +$1.39K ﹤0.01% 2161
2016
Q2 		$144K Buy
26,443
+18,301
+225% +$128K ﹤0.01% 2296
2016
Q1 		$69K Buy
8,142
+4,360
+115% +$30.9K ﹤0.01% 2187
2015
Q4 		$37K Buy
3,782
+843
+29% +$7.6K ﹤0.01% 2220
2015
Q3 		$41K Hold
2,939
– – ﹤0.01% 1992
2015
Q2 		$41K Buy
+2,939
New +$35.3K ﹤0.01% 2050

Other funds holding FOLD

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

BlackRock's FOLD Position: Q1 2026 in Review

BlackRock increased its Amicus Therapeutics (FOLD) stake by 4.2% in Q1 2026, buying an estimated $19.4M and bringing the position to 33,879,048 shares worth $490M. The position accounts for 0.01% of the portfolio, ranked #1118.

BlackRock first reported a position in FOLD in Q2 2015 and has held it in 44 quarters since. The position peaked at $505M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • BlackRock held 33,879,048 shares of Amicus Therapeutics worth $490M as of Q1 2026.
  • BlackRock bought 1,354,667 Amicus Therapeutics shares in Q1 2026, an estimated $19.4M.
  • Amicus Therapeutics made up 0.01% of BlackRock's portfolio in Q1 2026, its #1118 holding.
  • BlackRock first reported a position in Amicus Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • BlackRock's Amicus Therapeutics position peaked at $505M in Q4 2020.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.